Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NXS2

UPID:
QPCTL_HUMAN

ALTERNATIVE NAMES:
Golgi-resident glutaminyl-peptide cyclotransferase; isoQC

ALTERNATIVE UPACC:
Q9NXS2; Q53HE4; Q96F74

BACKGROUND:
The Glutaminyl-peptide cyclotransferase-like protein, known alternatively as isoQC and Golgi-resident glutaminyl-peptide cyclotransferase, is essential for pyroglutamyl peptide biosynthesis. This enzymatic activity ensures the formation of peptides with enhanced stability and function, crucial for maintaining the integrity of biological processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Glutaminyl-peptide cyclotransferase-like protein offers a promising avenue for drug discovery. By elucidating its role in peptide modification, researchers can identify novel therapeutic targets, potentially leading to breakthroughs in treating conditions associated with peptide dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.